Erlotinib therapy resulted in a significant improvement in median progression free survival, quality of life, and related symptom control compared to chemotherapy in an EGFR mutated population of advanced and metastatic NSCLC patients (EURTAC trial5; OPTIMAL trial6; ENSURE trial7). Here, EGFR is linked to non-small cell lung carcinoma.